Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

In this study, researchers observed that the sequence of maturity markers in normal boys showed specific time lags, with some markers appearing before and others after spermarche.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review discusses the role of nutraceuticals in combating skin aging but reports no new clinical results, focusing on their mechanisms of action and potential effectiveness for dermatologists.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This review discusses idiopathic hirsutism, potential underlying mechanisms, and various therapeutic approaches without providing new clinical results, and emphasizes the need for further research on well-defined patient groups.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.

This review discusses the clinical use of anti-androgen medications and highlights emerging evidence supporting plant-derived anti-androgens like spearmint tea for managing PCOS, but reports no new clinical results.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This study developed a mouse model for radiation cystitis that mimics human pathology and found that radiation exposure leads to increased urinary frequency and long-term weakening of urothelial integrity.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This review discusses the role of androgen hormones in skin and hair conditions and highlights the potential of antiandrogen therapies in dermatology, reporting no new results.

The authors concluded that components of metabolic syndrome were strongly associated with severe lower urinary tract symptoms in Latin American men, while alopecia was not an independent predictor.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.